Browse by author
Lookup NU author(s): Dr Khaver Qureshi,
Dr Mary Robinson,
Dr James Roberts,
Professor John Lunec,
Professor David Neal,
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Purpose: The prognostic value of p21 and p53 expression was evaluated for patients with muscle-invasive bladder cancer treated by radical radiotherapy. Methods and Materials: Sixty-eight paraffin-embedded sections from surgically resected tumors taken prior to irradiation were immunostained for p21 and p53. Results: Nuclear staining for p21 and p53 was demonstrated in 32/68 (47%) and 46/68 (68%) tumors, respectively. There was no correlation between p21 and p53 immunopositivity in this group (r = 0.067, p = 0.56). Patients were stratified into four distinct groups depending on staining for p21 and p53: p21+p53+, p21+p53-, p21-p53+, and p21-p53-. Patients with p21+p53+ tumors had the best prognosis with a 3-year survival of 82% compared to 12% for p21-p53+ tumors (p = 0.0031), 29% for p21+p53- tumors (p = 0.0108); and 45% for p21-p53- tumors (p = 0.0375). The p21+p53+ group also demonstrated significantly improved survival when a combined analysis was performed of p21-p53+, p21-p53-, and p21+p53- tumors (3-year survival = 30%, p = 0.0062). In a multivariate model, p21+p53+ tumors (p = 0.0108, relative risk [RR] = 5.18) and complete/partial response (p = 0.0019, RR = 3.76) were the only independent predictors of improved survival. Conclusions: With muscle-invasive bladder tumors treated by radical radiotherapy, stratification for p21 and p53 identifies distinct prognostic groups, with p21+p53+ tumors being associated with the best survival and p21-p53+ the worst. © 2001 Elsevier Science Inc.
Author(s): Qureshi, K.N., Griffiths, T.R.L., Robinson, M.C., Marsh, C., Roberts, J.T., Lunec, J., Neal, D.E., Mellon, J.K.
Publication type: Article
Publication status: Published
Journal: International Journal of Radiation: Oncology - Biology - Physics
Print publication date: 01/12/2001
ISSN (print): 0360-3016
ISSN (electronic): 1879-355X
PubMed id: 11728682
Altmetrics provided by Altmetric